BioSpace News Archive

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”)'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

Northwell Health and the Feinstein Institutes for Medical Research’s Christina Brennan, MD, senior vice president of clinical research, has received the Clinical Trial Europe’s Christine Pierre Clinical Trials Lifetime Achievement Award for her dedication to leading innovative, equitable and clinically meaningful clinical trials throughout her career and particularly her leadership in rolling out some of the first national COVID-19 clinical trials in 2020.

Annexon, Inc. announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock.

BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) in China.

Moleculin Biotech, Inc. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor and certain of the Company’s executive officers and directors to purchase 7,044,836 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Verisante Technology, Inc. is pleased to announce that at the 2023 Annual General Meeting held on December 18, 2023, in Vancouver, British Columbia, the Company’s shareholders voted in favour of all items of business.